Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Preferred Stock Liabilities (2019 - 2020)

Avidity Biosciences' Preferred Stock Liabilities history spans 2 years, with the latest figure at $136.9 million for Q1 2020.

  • For Q1 2020, Preferred Stock Liabilities changed N/A year-over-year to $136.9 million; the TTM value through Mar 2020 reached $136.9 million, changed N/A, while the annual FY2019 figure was $134.7 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $136.9 million in Q1 2020 per RNA's latest filing, up from $134.7 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $136.9 million in Q1 2020 to a low of $32.6 million in Q2 2019.